13.07.2011 • News

Mark C. Griffiths Named Carbogen Amcis CEO

New Carbogen Amcis CEO Mark Griffiths
New Carbogen Amcis CEO Mark Griffiths

Switzerland-based Carbogen Amcis, a pharmaceutical process development and API manufacturing company, announced that Mark C. Griffiths has been named chief executive officer, effective immediately. In his new role, Griffiths will have responsibility for the company's Swiss business and will report to Jay Vyas, managing director of Dishman Pharmaceuticals and Chemicals, Carbogen Amcis' parent company.

Griffiths has been associated with Carbogen Amcis as director of operations and chief executive officer for almost 10 years. Most recently, he has been working for the Dishman Group as operations advisor overseeing the design and construction of the group's large-scale manufacturing facilities for commercial supply of highly potent APIs (HPAPIs) in Shanghai, China, and Ahmedabad, India.

 

Company

Dishman Europe Ltd.

120 New Cavendish St.
W1W 6XX London

Company contact







Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

most read